Oncotarget

Research Papers:

P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer

Hiroaki Ono, Marc D. Basson and Hiromichi Ito _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:51301-51310. https://doi.org/10.18632/oncotarget.10117

Metrics: PDF 5064 views  |   HTML 6715 views  |   ?  


Abstract

Hiroaki Ono1, Marc D. Basson2, Hiromichi Ito1

1Department of Surgery, Michigan State University, College of Human Medicine, Lansing, MI, USA

2Departments of Surgery, Basic Science and Pathology, University of North Dakota, School of Medicine and Health Sciences, Grand Forks, ND, USA

Correspondence to:

Hiromichi Ito, email: [email protected]

Keywords: p300, gemcitabine, histone acetyl transferase, DNA damage repair, pancreatic cancer

Received: February 13, 2016     Accepted: May 17, 2016     Published: June 17, 2016

ABSTRACT

The transcriptional cofactor p300 has histone acetyltransferase activity (HAT) and has been reported to participate in chromatin remodeling and DNA repair. We hypothesized that targeting p300 can enhance the cytotoxicity of gemcitabine, which induces pancreatic cancer cell apoptosis by damaging DNA. Expression of p300 was confirmed in pancreatic cancer cell lines and human pancreatic adenocarcinoma tissues by western blotting and immunohistochemistry. When pancreatic cancer cells were treated with gemcitabine, p300 was recruited to chromatin within 24 hours, indicating the role in response to DNA damage. When p300 was gene-silenced with siRNA, histone acetylation was substantially reduced and pancreatic cancer cells were sensitized to gemcitabine. The selective p300 HAT inhibitor C646 similarly decreased histone acetylation, increased gemcitabine-induced apoptosis and thus enhanced the cytotoxicity of gemcitabine on pancreatic cancer cells. These findings indicate that p300 contributes to chemo-resistance of pancreatic cancer against gemcitabine and suggest that p300 and its HAT activity may be a potential therapeutic target to improve outcomes in patients with pancreatic cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10117